Simbarashe Mushambi Dube and Paula Dube v Douglas Nzombe Chiutsi and Healthwell Pharmacy (Pvt) Ltd t/a Clique Pharmacy

The plaintiffs (husband and wife) and the first defendant were shareholders in a pharmacy business (the second defendant). The first plaintiff held 34% shares, while the second plaintiff and first defendant each held 33%. The first defendant was the supervising pharmacist and managing director. The plaintiffs alleged that between August 2021 and March 2024, the first defendant misappropriated funds totaling US$284,036.21 through fictitious supplier payments (to "Varichem Kuda," "Varichem Martin," and "Varichem Cosmas") and US$15,621.37 through under-receiving of stock and manipulation of goods received vouchers. The plaintiffs claimed the first defendant admitted to causing prejudice of US$258,708 in a meeting held on 3 July 2024, one day after his release from eight days in remand prison on fraud charges. The first defendant sought to set aside the meeting minutes, alleging he was mentally incapacitated at the time due to post-traumatic stress disorder from his incarceration. The first defendant argued the suppliers in question were known "runners" used to import drugs from South Africa, a practice known to all directors but concealed from MCAZ (Medicines Control Authority) using pseudonyms.

• Whether the first defendant was mentally incapacitated when he attended the meeting on 3 July 2024 and whether the meeting minutes constitute a valid admission of liability
• Whether the first defendant breached his duty of loyalty under section 55 of the Companies and Other Business Entities Act
• Whether the first defendant is liable to the plaintiffs for damages under section 60 of the Companies and Other Business Entities Act in the sum of US$160,770.57
• Whether the plaintiffs proved the alleged misappropriation of funds through fictitious suppliers and manipulation of stock records

1. The minutes of the shareholders' meeting held on 3 July 2024 are set aside. 2. The plaintiffs' claim is dismissed with costs on an ordinary scale.

1. A person lacks mental capacity to contract where their state of mind renders them incapable of understanding and appreciating the transaction into which they purport to enter. Post-traumatic stress disorder, severe anxiety, and acute stress disorder can constitute mental incapacity vitiating consent to a contract or admission. 2. The test for mental capacity requires consideration of whether: (a) the person was incapable of estimating what was or was not a fair and beneficial bargain; (b) the person's state of mind was such that in common honesty they should not be held liable; and (c) the person was of unsound mind rendering them incapable of understanding and appreciating the transaction. 3. Whether a person had the requisite mental capacity at the time of contracting is a question of fact to be decided by the court based on all the circumstances. 4. Medical evidence, particularly from specialists such as psychiatrists, is highly relevant in determining mental capacity, though the ultimate determination remains with the court. 5. Directors of companies owe a duty of loyalty under section 55 of COBE, and members may bring direct actions under section 60 for damages caused by breach of this duty. 6. A party who deliberately misleads the court or withholds material information is unworthy of the court's protection, and adverse inferences will be drawn against such a party. 7. The burden of proof lies on the plaintiff to establish the damages claimed on a balance of probabilities.

The court observed that the distinction between executive directors and ordinary directors under the law is not significant, as all directors have an affirmative duty to safeguard and protect the interests of the company (citing Sambadza v AL-Shams Global BVI Limited). The court noted with concern the plaintiff's conduct in seeking to extract the defendant's immovable property as settlement while he was in custody and vulnerable, describing this as maximizing on the defendant's family's desperation. The court commented on the poor corporate governance practices at the pharmacy, including the use of pseudonyms to conceal prohibited procurement practices from MCAZ. The court observed that standard medical practice is for doctors to prepare contemporaneous notes rather than formal reports, with reports only being prepared upon specific request. The court noted that the forensic audit report did not comply with generally accepted audit standards and that the auditors appeared to have been provided with incomplete information (missing security registers). The court expressed skepticism about certain aspects of the ProPharm system's alleged inability to be manipulated, noting that the demonstration in court showed key information could be edited and saved.

This case is significant for establishing principles regarding mental capacity to contract in the context of post-traumatic stress disorder and duress. It demonstrates that severe mental distress, anxiety, and depression following incarceration can vitiate consent to a contract or admission. The judgment emphasizes the court's duty to protect parties who lack mental capacity at the expense of other contracting parties. The case also highlights the importance of candor and honesty in litigation, with the court drawing adverse inferences against a party who deliberately misleads the court on material facts. It further illustrates the application of sections 55 and 60 of the Companies and Other Business Entities Act regarding directors' duties of loyalty and shareholders' direct actions for damages. The case demonstrates that claims must be supported by credible evidence and that courts will scrutinize forensic reports and witness testimony carefully, particularly where there are inconsistencies or evidence of deliberate concealment of material facts.